|Bid||2.8600 x 2200|
|Ask||2.9400 x 800|
|Day's Range||2.8250 - 3.0600|
|52 Week Range||1.1000 - 13.2500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.30|
Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
The synthetic biology leader's healthy cash balance provides plenty of breathing room, but it won't last forever.